2-[1-[[1-(Carboxymethyl)cyclopropyl]methyl]-4-[2-[4-[4-(2,3,4,5,6-pentafluorophenyl)butoxy]phenyl]ethenyl]indol-3-yl]acetic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 2-[1-[[1-(Carboxymethyl)cyclopropyl]methyl]-4-[2-[4-[4-(2,3,4,5,6-pentafluorophenyl)butoxy]phenyl]ethenyl]indol-3-yl]acetic acid
• 英文别名: 2-[1-[[1-(carboxymethyl)cyclopropyl]methyl]-4-[2-[4-[4-(2,3,4,5,6-pentafluorophenyl)butoxy]phenyl]ethenyl]indol-3-yl]acetic acid
• 化学式: C₃₄H₃₀F₅NO₅
• 分子量: 627.6
• InChiKey: ZBWJKDQLYJMGDN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.9
• 重原子数：
  45
• 可旋转键数：
  14
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  88.8
• 氢给体数：
  2
• 氢受体数：
  10

文献信息

• ETHYNYLINDOLE COMPOUNDS
  申请人：OHMOTO Kazuyuki

  公开号：US20100160647A1

  公开（公告）日：2010-06-24

  As a compound having a potent oral activity and a long-lasting cysLT 1 /cysLT 2 receptor antagonistic activity, the compound of the formula (I): which exhibits potent antagonistic activity against the cysLT 1 /cysLT 2 receptor, and have long-lasting effects even in case of oral administration, and therefore is useful as an oral agent for preventing and/or treating a variety of diseases, for example, respiratory disease (for example, asthma (bronchial asthma, etc.), chronic obstructive pulmonary disease (COPD), pulmonary emphysema, chronic bronchitis, pneumonia (interstitial pneumonia, etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), apnea syndrome, allergic rhinitis, sinusitis (acute sinusitis, chronic sinusitis, etc.), pulmonary fibrosis, coughing (chronic coughing, etc.), and the like) was developed.

  作为一种具有强效口服活性和长效cysLT1/cysLT2受体拮抗活性的化合物，具有公式(I)的化合物表现出对cysLT1/cysLT2受体的强效拮抗活性，并且即使口服后也具有长效作用，因此可用作口服药剂预防和/或治疗各种疾病，例如呼吸道疾病（例如哮喘（支气管哮喘等）、慢性阻塞性肺病（COPD）、肺气肿、慢性支气管炎、肺炎（间质性肺炎等）、严重急性呼吸综合征（SARS）、急性呼吸窘迫综合征（ARDS）、呼吸暂停综合征、过敏性鼻炎、鼻窦炎（急性鼻窦炎、慢性鼻窦炎等）、肺纤维化、咳嗽（慢性咳嗽等）等）。
• Ethynylindole compounds
  申请人：ONO Pharmaceutical Co., Ltd.

  公开号：EP2206698A1

  公开（公告）日：2010-07-14

  As a compound having a potent oral activity and a long-lasting cysLT1/cysLT2 receptor antagonistic activity, the compound of the formula (I): which exhibits potent antagonistic activity against the cysLT1/cysLT2 receptor, and have long-lasting effects even in case of oral administration, and therefore is useful as an oral agent for preventing and/or treating a variety of diseases, for example, respiratory disease (for example, asthma (bronchial asthma, etc.), chronic obstructive pulmonary disease (COPD), pulmonary emphysema, chronic bronchitis, pneumonia (interstitial pneumonia, etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), apnea syndrome, allergic rhinitis, sinusitis (acute sinusitis, chronic sinusitis, etc.), pulmonary fibrosis, coughing (chronic coughing, etc.), and the like) was developed.

  作为一种具有强效口服活性和持久的 cysLT1/cysLT2 受体拮抗活性的化合物，式 (I) 的化合物： 该化合物对 cysLT1/cysLT2 受体具有强效拮抗活性，即使口服也具有长效作用，因此可用作预防和/或治疗多种疾病的口服制剂，例如呼吸系统疾病（如哮喘（支气管哮喘等）、慢性阻塞性肺疾病（COPs）、肺结核、肺癌等）。例如哮喘（支气管哮喘等）、慢性阻塞性肺病（COPD）、肺气肿、慢性支气管炎、肺炎（间质性肺炎等）、严重急性呼吸系统综合征（SARS）、急性呼吸窘迫综合征（ARDS）、呼吸暂停综合征、过敏性鼻炎、鼻窦炎（急性鼻窦炎、慢性鼻窦炎等）、肺纤维化、咳嗽（慢性咳嗽等）等）。
• US8115014B2
  申请人：——

  公开号：US8115014B2

  公开（公告）日：2012-02-14